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Abstract 
Background and Objectives: Obstructive sleep apnea (OSA) is associated with sleepiness, 
depression and reduced quality of life. However, it is unclear whether mild OSA has these 
negative impacts. Using data from the Apnea Positive Pressure Long-term Efficacy Study 
(APPLES), this study determined whether participants with mild OSA had greater sleepiness, 
more depressive symptoms and poorer quality of life in comparison to those without OSA. 
Methods: 239 evaluated for participation in APPLES with a baseline apnea hypopnea index 
(AHI) < 15 /hour were assigned to 1 of 2 groups: No OSA (N=40, AHI < 5 /hour) or Mild OSA 
(N=199, 5 to <15 /hour) based on their screening polysomnogram. Scores on their Epworth 
Sleepiness Scale (ESS), Stanford Sleepiness Scale (SSS), Hamilton Rating Scale for 
Depression (HAM-D), Profile of Mood States (POMS) and Sleep Apnea Quality of Life Index 
(SAQLI) were compared between groups.  
Results: There were no significant differences between the No OSA and Mild OSA groups on 
any of the 5 measures: ESS (OSA, 9.8 + 3.5 vs Mild OSA, 10.6 + 4.3, p=0.26), SSS,(2.8 + 0.9 
vs. 2.9 + 1.0, p=0.52)  HAM-D (4.6 + 3.0 vs. 4.9 + 4.7, p=0.27), POMS (33.5 + 22.3 vs. 28.7 + 
22.0, p=0.70), SAQLI (4.5 + 0.8 vs. 4.7 + 0.7, p=0.39). 
Conclusion: Individuals with mild OSA in this cohort do not have worse sleepiness, mood or 
quality of life in comparison to those without OSA. 
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Introduction 
 Obstructive sleep apnea (OSA) is an important sleep related breathing disorder with 
prevalence rates between 3-17% in men and 3-9% in women (1,2). With the rising trend of 
obesity, it is becoming increasingly more common (2,3). In a number of longitudinal cohort 
studies, severe OSA is associated with an increased incidence of hypertension, cardiovascular 
disease and death (4-9). It also is adversely associated with a number of neurocognitive and 
behavioral outcomes including depression (10), sleepiness (11), and poor quality of life (12). 
 The most commonly used metric to classify severity of OSA is the apnea-hypopnea 
index (AHI) which is the number of apnea or hypopnea events per hour of sleep. Persons with 
an AHI < 5 are not considered to have OSA (13). In contrast, an AHI > 5 and < 15, AHI > 15 and 
<30, and an AHI > 30 are classified as mild, moderate, and severe respectively (14). It is 
generally accepted that OSA can negatively impact mood, wakefulness and quality of life. 
However, it is unclear whether mild OSA can have such effects (10, 11, 15). Epidemiological 
studies have generally shown that individuals with OSA are sleepier than those without OSA 
(16). Existing data in persons with mild OSA referred tp sleep clinics are either limited primarily 
to assessments of sleepiness or have conflicting results (12, 17, 18). 
 The Apnea Positive Pressure Long-term Efficacy Study (APPLES) is a randomized, 
double-blinded, sham-controlled, multi-center trial of continuous positive airway pressure 
(CPAP) therapy designed to determine whether CPAP improves neurocognitive function over a 
6-month test period (19). The present study is an analysis of the relationship between 
assessments of mood, sleepiness and quality of life in those without OSA versus mild OSA at 
the baseline visit (pre-randomization) in those screened for participation in APPLES. Our intent 
was to determine whether there was any association between mild OSA and these domains. 
Methods 
PARTICIPANTS AND STUDY DESIGN:  
The study design, recruitment procedures, and inclusion and exclusion criteria for 
APPLES have been described extensively (19). The institutional review board (IRB) at each site 
approved the study protocol. Briefly, APPLES was a multisite study conducted at 5 clinical 
centers: Stanford University, Stanford, CA; University of Arizona, Tucson, AZ; Providence St. 
Mary Medical Center, Walla Walla, WA; St. Luke’s Hospital, Chesterfield, MO; and Brigham and 
Women’s Hospital, Boston, MA. Participants were recruited into the study primarily from patients 
scheduled into a regular sleep clinic for evaluation of possible OSA, and from local advertising. 
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Recruitment began in November 2003 and was completed in August 2008. Initial enrollment 
required age > 18 years and clinical symptoms of OSA, as defined by American Academy of 
Sleep Medicine (AASM) criteria (14).   At enrollment, participants underwent a screening 
diagnostic polysomnogram (PSG) and baseline neurocognitive testing including the 
standardized assessments described below. Only participants with an apnea hypopnea index 
(AHI) > 10 events per hour continued to the clinical trial and were randomized subsequently to 
sham or active CPAP for 6 months as previously reported (19). Excluded were individuals who 
had 1) prior OSA treatment with CPAP or surgery, 2) household members with current/past 
CPAP use, 3) a sleepiness-related automobile accident within the year prior to potential 
enrollment, (4) oxygen saturations < 75% for > 10% of the diagnostic polysomnogram (PSG) 
total sleep time; or (5) conditions or use of medications that could potentially affect 
neurocognitive function and/or alertness. For the present analysis, data from both randomized 
and non randomized participants at the time of the screening polysomnography visit were 
utilized. In addition to new information, some of the material related to sleepiness reported 
herein represent reanalysis of data in a different format from what has been published in a 
previous paper (20). 
POLYSOMNOGRAPHY 
Polysomnography was conducted as previously described using signals from a nasal 
pressure cannula, nasal/oral thermistor, thoracic and abdominal piezo bands, and a pulse 
oximeter to classify apnea and hypopnea events. An apnea was identified by a > 90% amplitude 
decrease from baseline of the nasal pressure signal lasting > 10 sec. Hypopneas were scored if 
there was a > 50%, but < 90% decrease from baseline of the nasal pressure signal, or if there 
was a clear amplitude reduction of the nasal pressure signal that did not reach the above 
criterion but it was associated with either an oxygen desaturation > 3% or an arousal, and the 
event duration was ≥ 10 seconds. Obstructive apneas were identified by persistence of chest or 
abdominal respiratory effort during flow cessation. Central apneas were noted if no 
displacement occurred on either the thoracic or abdominal channels. All studies were scored at 
the central reading center located at Stanford University. 
ASSESSMENTS OF SLEEPINESS 
Epworth Sleepiness Scale (ESS): The ESS is a validated self-administered 
questionnaire that asks an individual to rate his or her probability of falling asleep on a scale of 
increasing probability from 0 to 3 in 8 different situations (21). The scores for the 8 questions are 
summed to obtain a single score from 0 to 24 that is indicative of self-reported sleep propensity. 
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The ESS prior to randomization was administered at the time of the clinical evaluation and on 
the night of the diagnostic PSG. The value at the time of the diagnostic PSG was used, but if not 
available, then the value at the time of the clinical evaluation was substituted. 
Stanford Sleepiness Scale (SSS): The SSS asks a person to rate current moment 
sleepiness on a scale of one to seven (22). Each numerical rating has an associated descriptor, 
for example a rating of 1 is described as “feeling active, vital, alert, or wide awake,” while a 
rating of 7 is described as “no longer fighting sleep, sleep onset soon; having dream-like 
thoughts.” For APPLES the SSS was administered at 10:00, 12:00, 14:00, and 16:00 on the day 
following the diagnostic PSG; the variable analyzed was the mean score from these 4 trials. 
 ASSESSMENTS OF MOOD: 
 Profile of Mood States (POMS):  The POMS assesses mood by asking respondents how 
they feel at that moment according to a series of 65 descriptors such as “unhappy, tense or 
cheerful” (23). Possible responses are not at all, a little, moderately; quite a lot, extremely. Six 
mood states are used in the POMS: tension, depression, anger, vigor, fatigue, and confusion, 
which can be combined to form the total POMS mood disturbance score. Higher scores 
represent more negative mood states. For this analysis, total mood disturbance score was used.  
 Hamilton Rating Scale for Depression (HAM-D): The HAM-D is a validated 21-item 
clinician-administered assessment of the severity of depression (24). APPLES used a modified 
version of this test, the GRID Hamilton Rating Scale for Depression that was developed through 
a broad-based international consensus process to both simplify and standardize administration 
and scoring in clinical practice and research (25). In this scale, 17 items (e.g., depressed mood, 
suicide, work and anhedonia, retardation, agitation, gastrointestinal or general somatic 
symptoms, hypochondriasis, loss of insight or weight) are scored using either a 3- or 5-point 
scale based on intensity and frequency, and are summed to provide a single score. Higher 
scores reflect more depressive symptoms. 
 QUALITY OF LIFE ASSESSMENT:  
 Calgary Sleep Apnea Quality of LIfe Index (SAQLI): The SAQLI was developed as a 
sleep apnea specific quality of life instrument (26). It is a 35 item instrument that captures the 
adverse impact of sleep apnea on 4 domains: daily functioning, social interactions, emotional 
functioning and symptoms. Items are scored on a 7- point scale with “all of the time” and “not at 
all” being the most extreme responses. Item and domain scores are averaged to yield a 
composite total score between 1 and 7. Higher scores represent better quality of life. 
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STATISTICAL ANALYSES:  
For this analysis, participants who had an AHI < 5 were assigned to the No OSA group, 
and those who had an AHI > 5, but < 15 were assigned to the Mild OSA group. Body mass 
index (BMI) was computed as weight (kg)/height (m)2. Participants’ race/ethnicity were classified 
as self-reported white or non-white. Marital status was categorized as married or not married. 
For continuous variables, unadjusted comparisons between the No OSA and Mild OSA groups 
were made using Student’s t-test. Differences in proportions were assessed using the χ2 test. 
Analysis of covariance was performed to adjust for differences in study site, age and BMI. Data 
are expressed as mean + standard deviation (SD) or percentages. P < 0.05 was considered 
statistically significant. Analyses were performed using IBM SPSS Statistics Version 20 
(Chicago, IL).  
Results 
In Table 1 are shown the demographic data for the No OSA and Mild OSA groups. The 
groups were comparable with respect to gender, race, educational achievement, marital status 
and intelligence. By definition, the AHI for the Mild OSA group was significantly higher than for 
the No OSA group (10.9 + 2.5 vs. 3.1 + 1.4, p<0.01). However, participants in the No OSA were 
slightly younger than those in the Mild OSA group (42.1 + 15.1 vs. 47.1 + 13.1 years, p=0.03). 
There also was a slight trend for those in the Mild OSA group to have a higher BMI (27.3 + 4.5 
vs. 29.0 + 5.9 kg/m2, p=0.11). Some differences related to study site were noted as well. For the 
HAM-D, there was a trend for the mean score of both groups combined to be higher at the 
Brigham and Women’s Hospital site [N=51] in comparison to the University of Arizona site 
[N=59] (6.1 + 5.3 vs. 3.6 + 3.6, p=0.046). Similarly, there was a trend for the ESS to be lower at 
the University of Arizona site [N=61] comparison to the St. Luke’s Hospital Site [N=29] (9.2 + 33 
vs. 11.1 + 3.3, p=0.051). 
 Table 2 shows the comparisons between the No OSA and Mild OSA groups for the 
sleepiness, mood and quality of life metrics. There were no statistically significant differences 
observed for any of these variables. The table also shows the power in this study to detect 
clinically significant differences in these metrics. As shown, there is 90% power to demonstrate 
a 1.92, 0.52, 12.72, 1.90 and 0.45 difference between groups in the ESS, SSS, POMS, HAM-D 
and SAQLI respectively. Furthermore, although the No OSA group was slightly younger, there 
were no significant correlations between age and the ESS, SSS, POMS, HAM-D, and the 
SAQLI (r values between 0.04 and 0.11). 
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Discussion 
 In this analysis, we show that using a commonly accepted definition of mild OSA, 
sleepiness and mood are not different in comparison to persons without significant OSA. 
Furthermore, there was no evidence that mild OSA negatively impacts quality of life. These data 
suggest that mild OSA as currently defined has little adverse impact on sleepiness, mood and 
quality of life. 
 We observed that there were no differences in the ESS between participants with No 
OSA in comparison to those with Mild OSA. Results from other large cohorts are conflicting. Our 
results are consistent with those of Lopes et al who also did not find that the ESS was elevated 
in those with Mild OSA in a large population of patients undergoing PSG for suspected OSA 
(12). In contrast, a cohort of Chinese patients with mild OSA had a greater prevalence of 
subjective daytime sleepiness in comparison to those with primary snoring (18). However, the 
ESS was not higher in contrast to the Sleep Heart Health Study in which the ESS appeared to 
be greater in those with Mild OSA (16).  Similarly, excessive daytime sleepiness was more 
commonly reported among a cohort of Japanese women participating in a cardiovascular risk 
study (17). In this latter study, OSA status was determined using pulse oximetry and not PSG. A 
number of other studies also have reported sleepiness data in subjects with mild OSA. 
However, small sample sizes, populations with specialized characteristics, and lack of specific 
comparisons between persons with mild OSA and no OSA limit their interpretability (27-32). 
 In this study, mood as assessed by the POMS and the HAM-D was not worse in the Mild 
OSA group. Although depressive symptoms and use of anti-depressants are commonly noted 
among patients with OSA (33-35), studies of whether mood is affected by mild OSA are few.  In 
2 studies performed in patients seen in an otolaryngology clinic (27, 31), the Beck's Depression 
Inventory (BDI) was not different in comparison to either a control group or primary snorers. 
Similarly, in a group of elderly Koreans referred to a sleep clinic, the BDI was not elevated in 
comparison to an age-matched control group (36). Our findings extend these previous reports 
by showing that using two different assessments of mood, there was no adverse impact of mild 
OSA. 
 Quality of life in this study was not affected by mild OSA. In contrast, in a number of 
studies, quality of life assessed with various instruments is impaired in persons with OSA (37-
40). However, there are few studies in which the potential impact of mild OSA has been 
examined. In a relatively small study performed in patients from an otolaryngology clinic, scores 
on the SAQLI in patients with mild OSA were the same as a group of primary snorers (31). 
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Similarly, in an analysis of 461 elderly women who underwent PSG in the Study of Osteoporotic 
Fractures cohort, scores on the Functional Outcomes of Sleep Questionnaire were the same 
across tertiles of OSA severity (41).  Thus, our findings demonstrating a lack of association 
between mild OSA and quality of life are consistent with these previous studies. 
 Our failure to demonstrate an association between mild OSA and sleepiness, mood and 
quality of life provides additional data challenging the commonly used threshold for “defining 
disease” in the assessment of OSA. The traditional cutpoint of 5 originated more than 30 years 
ago when only apneic events were scored (42, 43). In the intervening years, it has been 
accepted that hypopneas have pathophysiologic significance and are now incorporated into the 
AHI (44). Additionally, some clinicians advocate including the more subtle respiratory effort 
related arousals into a broader respiratory disturbance index (RDI) (45). The data in this study 
suggest that at least for some domains of OSA symptomatology, mild OSA based on the 
application of current scoring criteria to older thresholds may in fact be part of a normal 
population. 
 Despite our findings, clinicians, insurers and policy makers should be cautioned about 
using the AHI as the sole metric in determining whether or not to treat an individual patient. The 
impact of OSA insofar as behavioral and neurocognitive domains are concerned appears to be 
quite heterogeneous. For example, 54% of individuals in the Sleep Heart Health Study with 
moderate to severe OSA were not sleepy on any one of 3 measures of sleepiness. Conversely, 
some individuals with less severe OSA may be sleepy (16). In our study, the mean ESS in both 
the No OSA and Mild OSA groups was above what would be expected for an unselected 
general population suggesting that other causes of sleepiness were present in the cohort (16). 
Thus, before deciding to initiate OSA specific treatment for Mild OSA, clinicians should consider 
whether there are other explanations for the patient’s symptoms, and not just treat the AHI. 
 This study does have three major limitations. First, it might be argued that our study was 
underpowered to detect small differences between the No OSA and Mild OSA groups. However, 
sufficient statistical power was present to detect clinically important differences (Table 2). For 
example, it has been proposed that the minimally important difference on repeated 
administrations of the SAQLI is approximately 1 (46). Our results demonstrated that we had 
90% power to detect a change of 0.5. Moreover, our findings are consistent with the limited 
number of studies previously performed. Second, our participants were a mixture of individuals 
recruited from sleep clinics and those responding to advertisements. Thus, they may not be 
representative of the general populace. Third, it is possible that the No OSA group included 
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some individuals who actually had mild OSA. Inasmuch as all participants were considered by 
clinicians to have symptoms consistent with OSA, some individuals in the No OSA group may 
have had falsely “negative” PSGs. Such misclassification would bias towards a null effect. The 
extent to which this occurred is not known, but night to night variability of the AHI is relatively 
low (47). Thus, we suspect this potential bias is small. Despite these limitations, however, the 
APPLES cohort was geographically and ethnically diverse, and had a representative gender 
distribution. 
 In conclusion, evidence from this analysis does not indicate that mild OSA has any 
impact on sleepiness, mood or quality of life. This raises concerns whether the current AHI 
criteria for distinguishing mild OSA from no clinically significant OSA needs to be reassessed. 
Nevertheless, additional comparisons between individuals who are truly without OSA symptoms 
and those with mild OSA as currently defined need to be performed before a final conclusion 
can be determined. 
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Table 1: Demographic Information 
	   	   	   	  
	   No	  OSA	   Mild	  OSA	   p	  
	   	   	   	  
N	   40	   199	   -­‐	  
Age	  (years)	   42.1	  +	  15.1	   47.1	  +	  13.1	   0.03	  
Male	  (N,%)/Female	  (N,%)	   19	  (47.5)/21	  (52.5)	   101	  (50.8)/98	  (49.2)	   0.73	  
Ethnicity	  (%	  Anglo)	   70.0	   70.9	   0.86	  
Years	  Education	   15.2	  +	  4.5	   15.7	  +	  3.2	   0.37	  
Married	  (%)	   60.0	   57.3	   0.32	  
AHI	  (#/Hour)	   3.1	  +	  1.4	   10.9	  +	  2.5	   <0.01	  
Full	  Scale	  WAIS	  IQ	   112.4	  	  +	  14.4	   112.9	  +	  13.7	   0.87	  
BMI	  (kg/m2)	   27.3	  +	  4.5	   29.0	  +	  5.9	   0.11	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Table 2: Sleepiness,	  Mood	  and	  Quality	  of	  Life	  in	  No	  OSA	  and	  OSA	  Groups 
	   	   	   	   	   	   	   	  
Assessment	   No	  OSA	   Mild	  OSA	   p	   Detectable	  Difference*	  
	   	   	   	   	   	   	   	  
Unadjusted	   N	   Mean	  (SD)	   N	   Mean	  (SD)	   	   80%	  power	   90%	  power	  
	   	   	   	   	   	   	   	  
Epworth	  Sleepiness	  Scale	   40	   9.8	  +	  3.5	   199	   10.6	  +	  4.3	   0.26	   1.66	   1.92	  
Stanford	  Sleepiness	  Scale	   34	   2.8	  +	  0.9	   192	   2.9	  +	  1.0	   0.52	   0.45	   0.52	  
Profile	  of	  Mood	  States	   31	   33.5	  +	  22.3	   149	   28.7	  +	  22.0	   0.27	   10.99	   12.72	  
Hamillton	  Depression	  Inventory	   40	   4.6	  +	  3.0	   196	   4.9	  +	  4.7	   0.70	   1.64	   1.90	  
Sleep	  Apnea	  Quality	  of	  Life	  Index	   34	   4.5	  +	  0.8	   195	   4.7+	  0.7	   0.39	   0.39	   0.45	  
*	  Using	  2	  sided	  α	  =	  0.05	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  
Adjusted**	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  
Epworth	  Sleepiness	  Scale	   40	   10.6	  +	  5.4	   199	   10.6	  +	  4.6	   0.86	   	   	  
Stanford	  Sleepiness	  Scale	   34	   2.6	  +	  1.4	   192	   2.9	  +	  1.1	   0.24	   	   	  
Profile	  of	  Mood	  States	   31	   32.1	  +	  27.7	   149	   27.4	  +	  25.0	   0.27	   	   	  
Hamillton	  Depression	  Inventory	   40	   4.8	  +	  5.8	   196	   4.8	  +	  4.8	   0.97	   	   	  
Sleep	  Apnea	  Quality	  of	  Life	  Index	   34	   4.7	  +	  1.1	   195	   4.7	  +	  0.7	   0.91	   	   	  
**Adjusted	  for	  Site,	  BMI	  and	  Age	   	   	   	   	   	   	   	  
 
 
 
 
 
